CommentAdd-on value of tirzepatide versus semaglutide
References (10)
- et al.
GLP-1 receptor agonists in the treatment of type 2 diabetes—state-of-the-art
Mol Metab
(2021) GLP-1 receptor agonists: which added value when increasing the dose?
Lancet Diabetes Endocrinol
(2021)- et al.
Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes
Lancet Diabetes Endocrinol
(2014) - et al.
9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2022
Diabetes Care
(2022) Treatment of type 2 diabetes and obesity on the basis of the incretin system: the 2021 Banting medal for scientific achievement award lecture
Diabetes
(2021)
There are more references available in the full text version of this article.
Cited by (9)
Comparative effects between old and new antidiabetic agents on metabolic- associated fatty liver disease (MAFLD)
2023, Diabetes Epidemiology and ManagementWeight variability and diabetes complications
2023, Diabetes Research and Clinical PracticeDual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes
2023, Annales d'EndocrinologieEffects of antidiabetic medications on metabolic‑associated fatty liver disease
2023, Revue Medicale SuisseTirzepatide: A Systematic Update
2022, International Journal of Molecular Sciences
© 2022 Elsevier Ltd. All rights reserved.